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mMRCAbstract Background: Respiratory muscle strength, occurrence of chronic dyspnea and hypox-
emia are still subjects of debate in liver cirrhosis. The loss of muscle mass in cirrhotic patients
may affect respiratory muscles thus contributing to chronic dyspnea in those patients.
Objective: To evaluate respiratory muscle strength, occurrence of hypoxemia and chronic dysp-
nea and their interrelationships in cirrhotic patients.
Patients and methods: One hundred HCV liver cirrhosis patients were recruited. Liver proﬁle,
serum creatinine, arterial blood gases (ABG), spirometry, maximal inspiratory (PiMAX) and expi-
ratory (PeMAX) pressures were measured. Grading of dyspnea was done using the modiﬁed med-
ical research council (mMRC) scale. The model for end-stage liver disease (MELD) score was
calculated for every patient.
Results: Patients’ mean MELD score was 16.9 ± 5.23. Mean mMRC score was 2.18 ± 0.81.
Hypoxemia was found in 81 (81%) patients. 39 (39%) and 35 (35%) patients had low PiMAX and
PeMAX, respectively, and 37 (37%) patients had low respiratory muscle strength (RMS). mMRC
score correlated negatively with RMS (r= 0.767, p< 0.001) and PO2 (r= 0.754, p< 0.001)
but correlated positively with MELD score (r= 0.9, p< 0.001). MELD score correlated negatively
with RMS (r= 0.824, p< 0.001) and PO2 (r= 0.824, P< 0.001). Patients without ascites had
signiﬁcantly higher PO2, PiMAX, PeMAX and RMS but lower mMRC values than ascitic patients.
Conclusion: Chronic dyspnea and hypoxemia are prevalent in cirrhotic patients and they are cor-
related with respiratory muscle weakness and liver disease severity. Ascitic patients have worse respi-
ratory muscle function and are more dyspneic than non ascitic patients.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Pulmonary symptoms and abnormalities occur commonly in
patients with liver cirrhosis regardless of etiology [1]. Arterial
blood gas and pulmonary function test abnormalities also
are common and are found in as many as 45–50% of cirrhotic
patients [2].
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with lung function: the tension of ascites moves the diaphragm
upward, making the ventilatory excursions difﬁcult and pleural
effusion which occurs in approximately 5% of cirrhotic
patients as a direct consequence of portal hypertension may
also cause abnormalities in pulmonary gaseous exchange [3].
In addition, speciﬁc pulmonary vascular changes associated
with liver disease and/or portal hypertension, i.e. hepatopul-
monary syndrome and portopulmonary hypertension, are
now well established [4].
Although chronic dyspnea is the predominant respiratory
symptom in patients with liver disease [5], there are scarce
reports on its prevalence and measurement using a widely
accepted tool as the modiﬁed medical research council mMRC
chronic dyspnea scale [6].
Patients with advanced liver cirrhosis are usually tiring eas-
ily, having chronic fatigue, protein wasting and muscle mass
loss [7]. The loss of muscle mass may affect both peripheral
and respiratory muscles [2]. Tests for measurement of respira-
tory pressures quantify the level of muscle weakness [8]. Due to
the fact that lung complications are frequent in hepatic dis-
eases, tests such as the measurement of maximum inspiratory
(PiMAX) and expiratory (PeMAX) pressures, are important
to evaluate pulmonary function and to delineate lung risk in
cirrhotic patients [9]. Hence, the aim of this study is to evaluate
respiratory muscle strength, occurrence of hypoxemia and
chronic dyspnea and their interrelationships in cirrhotic
patients.Patient and methods
The study included 100 adult patients with conﬁrmed HCV
liver cirrhosis based on lab and radiological studies referred
to for spirometry at Minouﬁya University Pulmonary Func-
tion Test Unit during the period from April 2013 to April
2014 as a part of investigating the cause of dyspnea or as a
part of the preoperative preparation for any operation.
Inclusion criteria were: (1) age 18 years and older; (2) the
ability to perform a full lung function testing satisfactorily;
and (3) stable clinical and functional state for at least four
weeks before testing. The exclusion criteria were: (1) cardio-
vascular disorders diagnosed by a cardiologist, (2) known
lung disease caused by conditions other than liver, such
as asthma or chronic obstructive pulmonary disease, inter-
stitial lung disease, pleural effusion, previous upper abdom-
inal or thoracic surgery, neuromuscular disorders, and daily
use of theophylline. Patients who cannot tolerate large pres-
sure swings in the thorax or abdomen caused by pulmonary
function test maneuvers (e.g. those with aneurysm, uncon-
trolled hypertension, urinary incontinence), were also
excluded. Before the beginning of the study, ethics approval
was obtained from the Minouﬁya Hospital’s Review Board
and a written informed consent was obtained from all
patients.
Liver disease severity was assessed according to the model
for end-stage liver disease (MELD, United Network for Organ
Sharing modiﬁcation) [10]. Serum laboratory data (used for
MELD score calculation) were measured maximum ±7 d the
day of respiratory testing.
Chronic dyspnea was rated according to the mMRC 5-
point scale [11]. The scale comprises statements that describealmost the entire range of respiratory disability from none
(Grade 0) to almost complete incapacity (Grade 4). The score
is the number that best ﬁts the patient’s level of activity.
Arterial blood gas sampling was done before spirometry
during rest, at room air. Hypoxemia was considered to be pres-
ent when PaO2 was <80 mmHg. Simple spirometry was mea-
sured with spirometer (Quark PFT3, COSMED, Italy). Forced
expiratory ﬂow in the ﬁrst second (FEV1), and forced vital
capacity (FVC) were measured. All measurements were per-
formed according to the American Thoracic Society recom-
mendations and expressed as the percent of predicted values
based on age, sex and height. Clinically signiﬁcant restrictive
lung disease was deﬁned when an abnormal FVC with normal
FEV1/FVC was observed [12].
Respiratory muscle strength was assessed by measuring
PiMAX and PeMAX using the same spirometer according to
the published protocols [13,14]. The PiMAX/PeMAX valve
was connected to the breathing valve connector on the front
panel of the Quark apparatus and the ﬂow meter was inserted
into the valve. Then, the gas cylinder containing O2 100% driv-
ing the valve was opened with the patient seated, wearing a
nose clip. The PiMAX/PeMAX maneuver was to tell the
patient to breathe normally for some time then inspire/expire
with the maximum force against the shutter until it opens auto-
matically. The determinations were repeated until 5 measure-
ments varying by <5% and the best value achieved was
considered in the data analysis. Respiratory muscle strength
was calculated as the arithmetic mean of PiMAX (% of pre-
dicted) and PeMAX (% of predicted).
Statistical methodology
Using SPSS version 17 (SPSS Inc., Chicago, IL, USA), data
were described as mean ± standard deviation for quantitative
variables and as frequency and percentage for qualitative vari-
ables. Student’s t-test and Pearson correlation coefﬁcient were
used. P value <0.05 was considered signiﬁcant.
Results
The current study included 100 patients with conﬁrmed HCV
liver cirrhosis. Patients with a mean age of 49.6 ± 8.62 years
included 61 (61%) males and 39 (39%) females. 36 (36%)
patients were not ascitic while 64 (64%) patients had ascites.
18 (18%) patients were Child A, 35 (35%) Child B and
47 (47%) Child C. Patients’ mean MELD score was
16.9 ± 5.23 (Table 1).
Patients’ mean mMRC score was 2.18 ± 0.81 with 44
(44%) patients reporting grade 2 dyspnea, 33 (33%) patients
grade 3 dyspnea, 19 (19%) patients grade 1 dyspnea while 3
(3%) patients grade 4 dyspnea. An analysis of ABG ﬁndings
in our patients revealed hypoxemia in 81 (81%) patients
(Table 2).
As regards pulmonary function tests and respiratory muscle
strength assessment: 39 (39%) patients had low PiMAX
(deﬁned as PiMAX< 80% predicted), 35 (35%) patients
had low PeMAX (deﬁned as PeMAX< 80% predicted) and
37 (37%) patients had low RMS (deﬁned as RMS< 80%
predicted) (Table 3).
Concerning the interrelationship between dyspnea, hypox-
emia, respiratory muscle strength (RMS) and liver disease
Table 1 Demographic, anthropometric and lab characteristics
of the study population.
Parameter Results
Age 49.6 ± 8.62 years
Sex Male 61
Female 39
Albumin 2.6 ± 0.65 gm/dl
Total bilirubin 4.138 ± 3.205 mg/dl
INR 1.58 ± 0.335
Creatinine 1.105 ± 0.788 mg/dl
Ascites Absent 36
Present 64
Child Pugh Child A = 18
Child B = 35
Child C = 47
MELD 16.9 ± 5.23
Height 168.01 ± 8.224 cm
Weight 73.62 ± 8.0237 kg
BMI 26.13 ± 2.724
INR: international normalized ratio, MELD: model for liver dis-
ease severity, BMI: body mass index.
Table 3 Pulmonary function test.
Parameter Results
FEV1 2.92 ± 0.044 L
FEV1 (% of predicted) 88.46 ± 0.57%
FVC 3.55 ± 0.051 L
FVC (% of predicted) 87.62 ± 0.42%
FEV1/FVC 82.27 ± 0.51
PiMAX 76.46 ± 13.91 cm H2O
PiMAX (% of predicted) 83.94 ± 11.66%
Low (<80%) = 39 patients
PeMAX 112.56 ± 18.32 cm H2O
PeMAX (% of predicted) 83.34 ± 11.79%
Low (<80%) = 35 patients
RMS 83.64 ± 11.44%
Low RMS (<80%) = 37 patients
FEV1: forced expiratory ﬂow in the ﬁrst second, FVC: forced vital
capacity, PiMAX: maximal inspiratory pressure, PeMAX: maximal
expiratory pressure, RMS: respiratory muscle strength.
Figure 1 Correlation between dyspnea (mMRC) and RMS.
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lated negatively with RMS (r= 0.767, p< 0.001) (Fig. 1),
PeMAX (r= 0.726, p< 0.001), PiMAX (r= 0.772,
p< 0.001) and PO2 (r= 0.754, p< 0.001) (Fig. 2), while
it correlated positively with MELD score (r= 0.9,
p< 0.001) (Fig. 3). PO2 correlated negatively with MELD
score (r= 0.852, p< 0.001) (Fig. 4) and correlated posi-
tively with RMS (r= 0.816, p< 0.001) (Fig. 5). MELD score
correlated negatively with RMS (r= 0.824, p< 0.001)
(Fig. 6). MELD score correlated negatively with PeMAX
and PiMAX (r= 0.787, r= 0.822 with p< 0.001)
(Table 4).
Comparing patients with ascites (n= 36) and those without
ascites (n= 64), we found that patients without ascites have
higher PO2 (75.33 ± 7.83 vs 70.09 ± 6.79, p= 0.0007), higher
PiMAX (87.19 ± 13.62 vs 82.11 ± 10.06, p= 0.0357), higher
PeMAX (86.44 ± 13.48 vs 81.59 ± 10.43, p= 0.0477) and







mMRC dyspnea grading score 2.18 ±
mMRC: modiﬁed medical research council.while ascitic patients were more dyspneic than non ascitic
(2.36 ± 0.74 vs 1.86 ± 0.83, p= 0.0027) (Table 5).ulation.
0.034 Normal PH= 54
High PH= 46
7.198 mmHg Low PCO2 = 48
Normal PCO2 = 52
7.58 mmHg Low PO2 = 81
Normal PO2 = 19
1.35 meq/l
1.56%
0.81 Grade 0 = 1 patient
Grade 1 = 19 patients
Grade 2 = 44 patients
Grade 3 = 33 patients
Grade 4 = 3 patients
Figure 2 Correlation between dyspnea (mMRC) and PO2.
Figure 3 Correlation between dyspnea (mMRC) and MELD.
Figure 4 Correlation between PO2 and MELD score.
Figure 5 Correlation between RMS and PO2.
Figure 6 Correlation between MELD and RMS.
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Numerous mechanisms for the occasional association between
liver cirrhosis, dyspnea and hypoxemia have been suggested astoday we know that there is no simple mechanism to explain
this association and that probably many factors have a role
in its pathogenesis [15].
In our study hypoxemia was found in 81% of the patients.
PO2 correlated negatively with MELD score (r= 0.852,
p< 0.001) and mMRC score (r= 0.754, p< 0.001). How-
ever, it correlated positively with RMS (r= 0.816,
p< 0.001). The prevalence of hypoxemia in cirrhotic patients
varied among studies [15–21] ranging from 13.9% to 60%. The
discrepancy between our results and those of others can be
explained by a difference in the severity of the disease in the
patients studied. Our study population consisted of a broad
spectrum of patients with cirrhosis. 18 (18%) patients were
Child A, 35 (35%) Child B and 47 (47%) Child C. Many
patients who were enrolled in our study have reached an
advanced state of the disease and many of them were candi-
dates for liver transplantation. A potential variation in the def-
inition of hypoxemia between different laboratories might be
another explanation.
In the absence of primary lung disease, the major causes of
arterial hypoxemia in cirrhosis and portal hypertension may be
pulmonary arteriovenous shunting, portopulmonary shunting,
and intrapulmonary vascular abnormalities, limited diffusion
Table 4 Interrelationships between mMRC, PO2, MELD and RMS.
Parameter MELD Parameter RMS Parameter mMRC
r p r p r p
mMRC 0.9 <0.001 mMRC 0.767 <0.001 PeMAX 0.726 <0.001
PO2 0.852 <0.001 PO2 0.816 <0.001 PiMAX 0.772 <0.001
PeMAX 0.787 <0.001 MELD 0.824 <0.001 PO2 0.754 <0.001
PiMAX 0.822 <0.001
mMRC=modiﬁed medical research council, RMS= respiratory muscle strength, PiMAX: maximal inspiratory pressure, PeMAX: maximal
expiratory pressure, MELD=model of end stage liver disease.
Table 5 Comparison between ascitic and non ascitic patients.
Parameter Non ascetic (n= 36) Ascitic (n= 64) P value
PO2 75.33 ± 7.83 70.09 ± 6.79 0.0007
mMRC 1.86 ± 0.83 2.36 ± 0.74 0.0027
PiMAX 87.19 ± 13.62 82.11 ± 10.06 0.0357
PeMAX 86.44 ± 13.48 81.59 ± 10.43 0.0477
RMS 86.82 ± 13.18 81.85 ± 10.01 0.0365
mMRC=modiﬁed medical research council, PiMAX: maximal
inspiratory pressure, PeMAX: maximal expiratory pressure,
RMS= respiratory muscle strength.
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the other hand, cirrhotic patients are usually hyperkinetic and
in some patients, the expected hypoxemia may be surprisingly
compensated by hyperventilation and increased circulation
[23]. Moreover, no demonstrable cause of hypoxemia can be
established in some cirrhotic patients with hypoxemia [24]. In
Ghayumi et al. study [18] there was a lack of correlation
between the degree of hypoxemia and pulmonary function
tests and the Child-Pugh score, all these ﬁndings raise the sus-
picion that some unknown mechanisms still exist in the path-
ogenesis of the hypoxemia in cirrhotic patients.
Patients in our study complained of chronic dyspnea of
varying severity (range 0:4) with their mean mMRC score
2.18 ± 0.81 and grade 2 dyspnea being the most prevalent,
as it was found in 44 (44%) patients. mMRC correlated posi-
tively with MELD score (r= 0.900, p< 0.001) and MELD
score correlated negatively with RMS (r= 0.824,
p< 0.001). These go in contrast with the study by Colle
et al. [21], and Charalabopoulos et al. [25] as none of their cir-
rhotic patients complained of dyspnea and to be compared
with the study by Kaltsakas et al. [6] with 88% of their patients
complaining of dyspnea. This may be explained by the differ-
ent dyspnea scales used between these studies and differences
in liver disease severity of the studied populations.
When assessing the respiratory muscle strength, we found
that PeMAX, PiMAX and RMS indices were below normal
in 35%, 39% and 37% of patients, respectively, and patients’
mMRC dyspnea grade correlated negatively with RMS
(r= 0.767, p< 0.001), PeMAX (r= 0.726, p< 0.001)
and PiMAX (r= 0.772, p< 0.001). MELD score correlated
negatively with RMS (r= 0.824, p< 0.001), PeMAX and
PiMAX (r= 0.787, r= 0.822 with p< 0.001). These
results are close to those reported by Kaltsakas et al. [6],
who reported PeMAX, PiMAX and RMS indices below nor-
mal in 30%, 38%, and 35% of their patients, respectively,
and mMRC score of their patients signiﬁcantly negativelycorrelated with PeMAX, PiMAX, and RMS (r= 0.53,
P< 0.001; r= 0.42, P< 0.01; r= 0.51, P< 0.001,
respectively). These ﬁndings are consistent also with those of
Hourani et al. [2] who measured respiratory muscle strength
in 116 patients with severe liver disease of varying etiologies
and found a decreased maximal inspiratory pressure in 56%
of them. A possible explanation for this fatigue could be the
loss of muscle mass, but it could also be related to the reduc-
tion in mitochondrial oxidative capacity, which results in per-
sistent physical deconditioning and cachexia [26,27]. The loss
of muscle mass may affect both peripheral and respiratory
muscles [2].
Furthermore, comparing the subgroups of ascitic patients
with non-ascitic patients, we found that all respiratory muscle
indices measured (PeMAX, PiMAX and RMS) were found
signiﬁcantly decreased in ascites patients than in non ascitic
patients with a p value of 0.0477, 0.0357 and 0.0365, respec-
tively. This also agrees with Prezant et al. [28] who studied
the effect of ascites on the diaphragmatic action in patients
undergoing continuous ambulatory peritoneal dialysis, a situ-
ation that from a mechanical point of view is similar to ascites.
They reported that an increase of the volume of dialysate
caused an increase in the PiMAX and they explained this by
(1) the elevation of the diaphragm in the thorax by the high
intra-abdominal pressure could lengthen diaphragmatic ﬁbers,
increasing the area of apposition of the diaphragm to the rib
cage and improving the length–tension relationship of the
diaphragm; and (2) the presence of liquid in the abdomen
could decrease abdominal compliance, thus providing a more
effective fulcrum for the diaphragmatic action.
In contrast to these results, Hourani et al.’s [2] study
showed lack of effects of large volume paracentesis on
inspiratory muscle strength suggesting that other mechanisms
linked to liver disease are probably involved in determining
inspiratory muscle weakness. In this context, the metabolic
alterations characteristic of liver cirrhosis (such as hypopro-
teinemia and electrolyte abnormalities) might play a role, as
conﬁrmed by the observation of muscle wasting in patients
with liver diseases [2], and, in particular, in cirrhotic patients
[29]. Finally, one has also to consider that PiMAX and
PeMAX are effort-dependent maneuvers, so that variations
in effort pre- and postparacentesis might inﬂuence the
measure.
Finally we can conclude that: (1) chronic dyspnea and hyp-
oxemia are prevalent in liver cirrhosis patients and they are
correlated with liver disease severity and respiratory muscle
weakness, (2) Cirrhotic patients with ascites had worse respira-
tory muscle strength and they are more dyspenic and hypoxic
than non ascitic patients. So it is recommended that every
1064 S.A. Abdel-bary et al.cirrhotic patient especially with ascites planning to undergo an
operation, is to be evaluated with ABG and pulmonary func-
tion tests with respiratory muscle strength indices to assess
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